-34%

est. 2Y upside i

HealthcareSeries D+

Rank

#3017

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: High

The equity upside is negative expected at -34% over 2 years, driven by a high entry multiple (9.15x) and slowing growth.

Last updated: July 3, 2026

Bull (10%)+10%

Multiple holds at 9x due to successful IPO and category leadership, driving exit to $5.5B; net return ~10% after 15% dilution.

Base (45%)-27%

Multiple compresses to 6x as growth slows; exit $3.7B yields -27% net return after dilution.

Bear (45%)-51%

Multiple falls to 4x amid competitive pressure from Big Tech and regulatory risks; exit $2.4B yields -51% net return after dilution.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Funding Intensity

2040%

Total preferred stock of $866M represents 20.4% of current valuation, creating a high overhang for common stock.

Dilution Risk

moderate

Anticipated IPO or follow-on raise likely dilutes common holders by ~15%.

Secondary Liquidity

moderate

Secondary market transactions indicate some liquidity, but not guaranteed for employees.

View all 261 open roles at Doctolib →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Doctolib's data — designed to show you've done your homework.

  • 1

    “How will Doctolib defend against Big Tech entrants like Microsoft and Google in healthcare?”

  • 2

    “What is the path to profitability given the subscription model and high operating costs?”

  • 3

    “How does the equity structure (preference stack, secondary liquidity) affect employee upside?”

Community

Valuation Sentiment

Our model estimates -34% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.